ID

23073

Beschreibung

Randomized Evaluation of the Effectiveness of Clozapine and Aripiprazole Versus Clozapine and Haloperidol in the Treatment of Schizophrenia; ODM derived from: https://clinicaltrials.gov/show/NCT00395915

Link

https://clinicaltrials.gov/show/NCT00395915

Stichworte

Versionen (1)
  1. 22.06.17 22.06.17 -
Hochgeladen am

22. Juni 2017

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY 4.0
Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Zurück zu Modell Kommentaren
Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Eligibility Schizophrenia NCT00395915

Englisch

Eligibility Schizophrenia NCT00395915

1 Formulare  
Inclusion Criteria
Beschreibung

Inclusion Criteria

Alias
UMLS CUI
C1512693
1. current treatment with clozapine for the primary indication of schizophrenia (clinical diagnosis, guided by dsm-iv criteria).
Beschreibung

Clozapine | Schizophrenia

Datentyp

boolean

Alias
UMLS CUI [1]
C0009079
UMLS CUI [2]
C0036341
2. treatment with clozapine for at least six months at a stable dose of 400 mg or more per day, unless the size of the dose was limited by side-effects.
Beschreibung

Clozapine | Dose Stable U/day | Dose Limited caused by Adverse effects

Datentyp

boolean

Alias
UMLS CUI [1]
C0009079
UMLS CUI [2,1]
C0178602
UMLS CUI [2,2]
C0205360
UMLS CUI [2,3]
C0456683
UMLS CUI [3,1]
C0178602
UMLS CUI [3,2]
C0439801
UMLS CUI [3,3]
C0015127
UMLS CUI [3,4]
C0879626
3. unsatisfactory benefit from clozapine treatment, as indicated by the presence of positive symptoms (delusions, hallucinations, abnormal behaviour, clinical diagnosis)
Beschreibung

Clozapine Benefit Unsatisfactory | Symptoms Positive Present | Delusions | Hallucinations | Abnormal behavior | Diagnosis, clinical

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0009079
UMLS CUI [1,2]
C0814225
UMLS CUI [1,3]
C0439856
UMLS CUI [2,1]
C1457887
UMLS CUI [2,2]
C1514241
UMLS CUI [2,3]
C0150312
UMLS CUI [3]
C0011253
UMLS CUI [4]
C0018524
UMLS CUI [5]
C0233514
UMLS CUI [6]
C0332140
4. age 18 and above.
Beschreibung

Age

Datentyp

boolean

Alias
UMLS CUI [1]
C0001779
5. agreement between investigator and patient to enter the study.
Beschreibung

Study Subject Participation Status Agreement Investigator

Datentyp

boolean

Alias
UMLS CUI [1,1]
C2348568
UMLS CUI [1,2]
C4255373
UMLS CUI [1,3]
C0035173
6. the patient is normally resident in italy.
Beschreibung

Residence

Datentyp

boolean

Alias
UMLS CUI [1]
C0237096
7. it is considered clinically reasonable to try combination treatment with clozapine and aripiprazole or with clozapine and haloperidol.
Beschreibung

Combined Modality Therapy | Clozapine | aripiprazole | Haloperidol

Datentyp

boolean

Alias
UMLS CUI [1]
C0009429
UMLS CUI [2]
C0009079
UMLS CUI [3]
C0299792
UMLS CUI [4]
C0018546
8. uncertainty about which trial treatment would be best for the participant.
Beschreibung

Therapeutic procedure Uncertain

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0087111
UMLS CUI [1,2]
C0087130
9. no medical disorder or condition contraindicates either of the investigational drugs.
Beschreibung

Investigational New Drugs Medical contraindication Absent

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0013230
UMLS CUI [1,2]
C1301624
UMLS CUI [1,3]
C0332197
10. agreement between investigator and patient to discontinue any antipsychotic drugs other than clozapine (including long-acting antipsychotic drugs).
Beschreibung

Antipsychotic Agents To be stopped | Antipsychotic Agents Active Long-term To be stopped | Clozapine Excluded

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0040615
UMLS CUI [1,2]
C1272691
UMLS CUI [2,1]
C0040615
UMLS CUI [2,2]
C0205177
UMLS CUI [2,3]
C0443252
UMLS CUI [2,4]
C1272691
UMLS CUI [3,1]
C0009079
UMLS CUI [3,2]
C2828389
Zum Seitenanfang zurückkehren

Ähnliche Modelle

Eligibility Schizophrenia NCT00395915

1 Formulare
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
C1512693 (UMLS CUI)
Clozapine | Schizophrenia
Item
1. current treatment with clozapine for the primary indication of schizophrenia (clinical diagnosis, guided by dsm-iv criteria).
boolean
C0009079 (UMLS CUI [1])
C0036341 (UMLS CUI [2])
Clozapine | Dose Stable U/day | Dose Limited caused by Adverse effects
Item
2. treatment with clozapine for at least six months at a stable dose of 400 mg or more per day, unless the size of the dose was limited by side-effects.
boolean
C0009079 (UMLS CUI [1])
C0178602 (UMLS CUI [2,1])
C0205360 (UMLS CUI [2,2])
C0456683 (UMLS CUI [2,3])
C0178602 (UMLS CUI [3,1])
C0439801 (UMLS CUI [3,2])
C0015127 (UMLS CUI [3,3])
C0879626 (UMLS CUI [3,4])
Clozapine Benefit Unsatisfactory | Symptoms Positive Present | Delusions | Hallucinations | Abnormal behavior | Diagnosis, clinical
Item
3. unsatisfactory benefit from clozapine treatment, as indicated by the presence of positive symptoms (delusions, hallucinations, abnormal behaviour, clinical diagnosis)
boolean
C0009079 (UMLS CUI [1,1])
C0814225 (UMLS CUI [1,2])
C0439856 (UMLS CUI [1,3])
C1457887 (UMLS CUI [2,1])
C1514241 (UMLS CUI [2,2])
C0150312 (UMLS CUI [2,3])
C0011253 (UMLS CUI [3])
C0018524 (UMLS CUI [4])
C0233514 (UMLS CUI [5])
C0332140 (UMLS CUI [6])
Age
Item
4. age 18 and above.
boolean
C0001779 (UMLS CUI [1])
Study Subject Participation Status Agreement Investigator
Item
5. agreement between investigator and patient to enter the study.
boolean
C2348568 (UMLS CUI [1,1])
C4255373 (UMLS CUI [1,2])
C0035173 (UMLS CUI [1,3])
Residence
Item
6. the patient is normally resident in italy.
boolean
C0237096 (UMLS CUI [1])
Combined Modality Therapy | Clozapine | aripiprazole | Haloperidol
Item
7. it is considered clinically reasonable to try combination treatment with clozapine and aripiprazole or with clozapine and haloperidol.
boolean
C0009429 (UMLS CUI [1])
C0009079 (UMLS CUI [2])
C0299792 (UMLS CUI [3])
C0018546 (UMLS CUI [4])
Therapeutic procedure Uncertain
Item
8. uncertainty about which trial treatment would be best for the participant.
boolean
C0087111 (UMLS CUI [1,1])
C0087130 (UMLS CUI [1,2])
Investigational New Drugs Medical contraindication Absent
Item
9. no medical disorder or condition contraindicates either of the investigational drugs.
boolean
C0013230 (UMLS CUI [1,1])
C1301624 (UMLS CUI [1,2])
C0332197 (UMLS CUI [1,3])
Antipsychotic Agents To be stopped | Antipsychotic Agents Active Long-term To be stopped | Clozapine Excluded
Item
10. agreement between investigator and patient to discontinue any antipsychotic drugs other than clozapine (including long-acting antipsychotic drugs).
boolean
C0040615 (UMLS CUI [1,1])
C1272691 (UMLS CUI [1,2])
C0040615 (UMLS CUI [2,1])
C0205177 (UMLS CUI [2,2])
C0443252 (UMLS CUI [2,3])
C1272691 (UMLS CUI [2,4])
C0009079 (UMLS CUI [3,1])
C2828389 (UMLS CUI [3,2])
Zum Seitenanfang zurückkehren 

Kontakt

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Hilfe

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video